TREATMENT OF H-RAS-DRIVEN TUMORS

摘要

The present disclosure describes a compositions and methods for treatment of Hras-driven cancers. Administration of a farnesyltransferase inhibitor, for example, tipifarnib, alone or in combination with a MEK inhibitor can reduce tumor size and tumor growth in cancers such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC).

主权项

1. A method for reducing tumor burden in a subject with a tumor that has a constitutively activating mutation of Hras, the method comprising administering to the subject a therapeutically effect amount of a farnesyltransferase inhibitor (FTI).